Skip to content

Study on the Improvement of Neurological Function by Astragalus Injection Combined with Transcutaneous Electrical Acupoint Stimulation in Patients After Traumatic Intracerebral Hemorrhage Surgery

Study on the Improvement of Neurological Function by Astragalus Injection Combined with Transcutaneous Electrical Acupoint Stimulation in Patients After Traumatic Intracerebral Hemorrhage Surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000816
Enrollment
Unknown
Registered
2026-03-30
Start date
2025-07-30
Completion date
Unknown
Last updated
2026-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Traumatic intracerebral hemorrhage

Interventions

Con group:NA
AM group:Astragalus Injection treatment
TEAS group:Transcutaneous Electrical Acupoint Stimulation (TEAS) treatment
AM+TEAS group:Astragalus Injection combined with Transcutaneous Electrical Acupoint Stimulation (TEAS) treatment

Sponsors

Department of Anesthesiology , Tangdu Hospital, Fourth Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1) A clear history of traumatic brain injury with a Glasgow Coma Scale (GCS) score = 4; 2) All cases were diagnosed with traumatic intracranial hematoma by CT examination; 3) Planned to undergo minimally invasive or craniotomy for intracranial hematoma evacuation; 4) Aged 18 to 65 years.

Exclusion criteria

Exclusion criteria: 1) Patients or their families refuse to participate in this study; 2) Patients with a history of mental disorders, epilepsy, Parkinson's disease, or myasthenia gravis; 3) Patients with brain parenchymal diseases such as intracranial tumors; 4) Patients allergic to or with contraindications to the study medication; 5) Patients with a body mass index (BMI) 30 kg/m²; 6) Pregnant or breastfeeding women; 7) Patients with severe traumatic brain injury (deep coma or GCS score < 4), or those complicated by refractory intracranial hypertension, severe multiple injuries, shock, etc.; 8) Patients concurrently participating in other clinical studies; 9) Patients with a history of alcoholism, drug abuse, or other conditions affecting cognitive function; 10) Patients with severe arrhythmias, such as atrial fibrillation or frequent premature ventricular contractions; 11) Patients with severe diseases of vital organs such as the heart, liver, or kidneys; Patients with skin damage, infections, or implanted electrophysiological devices.

Design outcomes

Primary

MeasureTime frame
Neurological Impairment Score;

Secondary

MeasureTime frame
The volume of hematoma in intracerebral hemorrhage;

Countries

China

Contacts

Public ContactGao Changjun

Department of Anesthesiology , Tangdu Hospital, Fourth Military Medical University

gaocj74@163.com13379227869

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: May 1, 2026